1. Home
  2. KRUS vs GERN Comparison

KRUS vs GERN Comparison

Compare KRUS & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$54.37

Market Cap

683.6M

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.34

Market Cap

753.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
GERN
Founded
2008
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.6M
753.3M
IPO Year
2019
1996

Fundamental Metrics

Financial Performance
Metric
KRUS
GERN
Price
$54.37
$1.34
Analyst Decision
Buy
Buy
Analyst Count
7
7
Target Price
$84.29
$3.00
AVG Volume (30 Days)
304.1K
6.8M
Earning Date
01-07-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$282,763,000.00
$183,403,000.00
Revenue This Year
$18.91
$147.42
Revenue Next Year
$20.16
$39.42
P/E Ratio
N/A
N/A
Revenue Growth
18.88
522.13
52 Week Low
$40.03
$1.04
52 Week High
$106.60
$3.68

Technical Indicators

Market Signals
Indicator
KRUS
GERN
Relative Strength Index (RSI) 53.45 53.73
Support Level $50.73 $1.30
Resistance Level $56.62 $1.37
Average True Range (ATR) 2.41 0.07
MACD 0.05 -0.01
Stochastic Oscillator 65.70 23.33

Price Performance

Historical Comparison
KRUS
GERN

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: